Wanbangde (002082.SZ): WP107 oral solution approved for clinical trials for the treatment of "myasthenia gravis"

Wisdom Finance News App News, Wanbangde (002082.SZ) announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Group Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's independently developed WP107 oral solution for the treatment of "myasthenia gravis" has been approved for clinical trial application.